Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT03741127
Active, not recruiting Phase 1

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

NCT03741127 · tracked via the Priya Life Science USA tracker
Sponsor
Poseida Therapeutics, Inc
Phase
Phase 1
Started
2018-10-29
Last updated
2026-03-04

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Rimiducid may be administered as indicated

Rimiducid may be administered as indicated: Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.

Study summary

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol. * Subject has provided informed consent. Exclusion Criteria: * None

Primary outcome measure(s)

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — Treatment with P-BCMA-101 through year 15
    Incidence and severity of treatment-emergent adverse events to evaluate the long-term safety of P-BCMA-101

Trial sites (13)

FacilityCityRegionStatus
University of California Davis Davis California
University of California, San Diego San Diego California
University of California San Francisco San Francisco California
Colorado Blood Cancer Institute Denver Colorado
University of Chicago Chicago Illinois
University of Kansas Cancer Center Westwood Kansas
University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland
Johns Hopkins University Baltimore Maryland
Wayne State - Karmanos Cancer Institute Detroit Michigan
University of Pennsylvania Philadelphia Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology Nashville Tennessee
Vanderbilt University Medical Center Nashville Tennessee
MD Anderson Cancer Center Houston Texas

More Poseida Therapeutics, Inc. trials in the USA

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Active, not recruiting
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma Active, not recruiting
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting

Other trials for the same condition

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) Active, not recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03741127 on ClinicalTrials.gov ↗ ← All trials in the USA